450 related articles for article (PubMed ID: 27658422)
1. Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Cassady K; Aboody KS
Mol Cancer Res; 2016 Dec; 14(12):1229-1242. PubMed ID: 27658422
[TBL] [Abstract][Full Text] [Related]
2. SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Aboody KS
Stem Cells Dev; 2017 Sep; 26(17):1236-1246. PubMed ID: 28610554
[TBL] [Abstract][Full Text] [Related]
3. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
5. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.
Singer E; Judkins J; Salomonis N; Matlaf L; Soteropoulos P; McAllister S; Soroceanu L
Cell Death Dis; 2015 Jan; 6(1):e1601. PubMed ID: 25590811
[TBL] [Abstract][Full Text] [Related]
6. Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Zhu Z; Du S; Du Y; Ren J; Ying G; Yan Z
J Neurochem; 2018 Jan; 144(1):93-104. PubMed ID: 29105080
[TBL] [Abstract][Full Text] [Related]
7. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Sehm T; Fan Z; Ghoochani A; Rauh M; Engelhorn T; Minakaki G; Dörfler A; Klucken J; Buchfelder M; Eyüpoglu IY; Savaskan N
Oncotarget; 2016 Jun; 7(24):36021-36033. PubMed ID: 27074570
[TBL] [Abstract][Full Text] [Related]
8. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
9. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Garcia CG; Kahn SA; Geraldo LHM; Romano I; Domith I; Silva DCLE; Dos Santos Assunção F; Ferreira MJ; Portugal CC; de Souza JM; Romão LF; Netto ADP; Lima FRS; Cossenza M
Mol Neurobiol; 2018 Aug; 55(8):6816-6833. PubMed ID: 29349577
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
[TBL] [Abstract][Full Text] [Related]
12. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).
Tsuchihashi K; Okazaki S; Ohmura M; Ishikawa M; Sampetrean O; Onishi N; Wakimoto H; Yoshikawa M; Seishima R; Iwasaki Y; Morikawa T; Abe S; Takao A; Shimizu M; Masuko T; Nagane M; Furnari FB; Akiyama T; Suematsu M; Baba E; Akashi K; Saya H; Nagano O
Cancer Res; 2016 May; 76(10):2954-63. PubMed ID: 26980765
[TBL] [Abstract][Full Text] [Related]
13. The X
Zheng Z; Luo G; Shi X; Long Y; Shen W; Li Z; Zhang X
Cell Oncol (Dordr); 2020 Feb; 43(1):95-106. PubMed ID: 31617161
[TBL] [Abstract][Full Text] [Related]
14. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Pyrko P; Schönthal AH; Hofman FM; Chen TC; Lee AS
Cancer Res; 2007 Oct; 67(20):9809-16. PubMed ID: 17942911
[TBL] [Abstract][Full Text] [Related]
15. Glial Glutamate Transporter-Mediated Plasticity: System x
Dahlmanns M; Dahlmanns JK; Savaskan N; Steiner HH; Yakubov E
Front Biosci (Landmark Ed); 2023 Mar; 28(3):57. PubMed ID: 37005761
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Zhou B; Bu G; Zhou Y; Zhao Y; Li W; Li M
Med Oncol; 2015 Jan; 32(1):378. PubMed ID: 25433945
[TBL] [Abstract][Full Text] [Related]
17. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
Pham AN; Blower PE; Alvarado O; Ravula R; Gout PW; Huang Y
J Pharmacol Exp Ther; 2010 Mar; 332(3):949-58. PubMed ID: 20007406
[TBL] [Abstract][Full Text] [Related]
20. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]